Figure 3.

Mean (± SD) serum pateclizumabpharmacokinetic profiles (A) and CXCL13 profiles (B) by cohort. CXCL13 is presented as the percentage change from baseline. Arrows indicate pateclizumabdoses. BL = baseline; CXCL13 = chemokine (C-X-C motif) ligand 13; IV = intravenously; LTα = lymphotoxin α; MAD = multiple ascending dose; SAD = single ascending dose; SC = subcutaneously.

Emu et al. Arthritis Research & Therapy 2012 14:R6   doi:10.1186/ar3554
Download authors' original image